Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The rat monoclonal antibody (mAb) YTH12.5, specific for the CD3 antigen complex on human T cells has been modified in order to improve its efficacy in human therapy. With the aim of rendering it less immunogenic, it has been humanized using the method of framework grafting. During this process sequence analysis of the YTH12.5 VL gene indicated that it was of the lambda subclass, however, it was markedly dissimilar from previously published rat and mouse V lambda gene sequences and may represent a new V lambda gene family. The humanization of this light chain represents the first successful reshaping of a lambda light chain V region. To improve the effector function of the antibody we have created a monovalent form (1 Fab, 1 Fc) using a novel method involving the introduction of an N-terminally truncated human IgG1 heavy chain gene into cells producing the humanized CD3 mAb. Comparison of the mono- and bivalent humanized mAb in a complement-mediated cell lysis assay revealed that the monovalent antibody mediated lysis of human T cell blasts whereas the bivalent form did not. The availability of a humanized, complement-fixing CD3 mAb may improve opportunities for human therapy, in the management of organ rejection, autoimmunity and the treatment of T cell lymphoma.

Original publication

DOI

10.1002/eji.1830211111

Type

Journal article

Journal

Eur J Immunol

Publication Date

11/1991

Volume

21

Pages

2717 - 2725

Keywords

Amino Acid Sequence, Animals, Antibodies, Monoclonal, Antigen-Antibody Reactions, Antigens, CD, Antigens, Differentiation, T-Lymphocyte, Base Sequence, CD3 Complex, Cloning, Molecular, Complement Activation, Cytotoxicity, Immunologic, Humans, Immunoglobulin Variable Region, Isoantibodies, Molecular Sequence Data, Rats, Receptors, Antigen, T-Cell, Recombinant Fusion Proteins, T-Lymphocytes, T-Lymphocytes, Cytotoxic